Kymera Therapeutics Announces Pricing of $275 Million Public Offering

Rhea-AI Summary

Kymera Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: KYMR), announced the pricing of its underwritten public offering of $275 million of shares of its common stock and pre-funded warrants to purchase shares of its common stock. The offering is expected to close on January 9, 2024, and the company intends to use the net proceeds for advancing its pipeline of preclinical and clinical degrader programs, working capital, and other general corporate purposes.

Insights

Financial Analyst

The public offering by Kymera Therapeutics signifies a strategic move to raise capital, indicative of the company's growth trajectory and potential expansion plans. The pricing of the offering at $25.25 per share and the decision to include pre-funded warrants as an alternative for certain investors underscore the company's approach to attract a diverse investor base while also providing a mechanism for future capital inflow, should these warrants be exercised.

From a financial perspective, the gross proceeds of approximately $275 million, prior to fees and expenses, will bolster Kymera's balance sheet. This is crucial for a clinical-stage biopharmaceutical company that typically incurs significant R&D expenses before generating revenue from approved products. The additional $41.25 million option for underwriters provides a buffer and potential further capital, reflecting confidence in the offering's success.

Investors will be assessing the impact of this capital raise on the company's valuation, dilution of existing shares and the progress of Kymera's pipeline. The use of proceeds for advancing clinical programs and potential strategic acquisitions or in-licensing deals suggests a proactive approach to growth, which could enhance the company's long-term value proposition.

Market Research Analyst

Targeted protein degradation (TPD) is an emerging field in drug development, offering a novel approach to treating diseases by selectively degrading disease-causing proteins. Kymera Therapeutics is positioned within this innovative segment and the success of their clinical degrader programs could have significant implications for the treatment of various diseases. The capital raised through this offering is expected to accelerate the development of Kymera's pipeline, which addresses large patient populations with unmet medical needs.

The company's strategic intent to potentially use a portion of the net proceeds for in-licensing or acquisitions suggests an aggressive pursuit of growth and competitive positioning. As the TPD market evolves, Kymera's actions could set industry benchmarks for strategic financing and pipeline advancement. Stakeholders will be keen to monitor the deployment of the raised funds and the resultant milestones achieved in the company's clinical and preclinical programs.

Biotechnology Legal Expert

The offering is conducted under an automatically effective shelf registration statement, which allows for a more streamlined process and quicker access to the market. This is a common strategy used by biotech companies to maintain flexibility in financing and to capitalize on favorable market conditions. The legal framework of the offering, including the role of leading financial institutions as bookrunning managers, suggests a well-structured and compliant approach to capital raising.

Furthermore, the legal stipulations that the offering will not constitute an offer to sell or a solicitation in jurisdictions where such actions would be unlawful, highlight the regulatory complexities involved in biopharmaceutical financing. Compliance with SEC regulations and state securities laws is paramount and the involvement of reputable financial institutions indicates due diligence in adhering to these regulations.

WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,250,495 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,640,594 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $25.25 per share and the pre-funded warrants are being sold at a public offering price of $25.2499 per pre-funded warrants, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Kymera from the offering are expected to be approximately $275 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters’ option to purchase additional shares. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional $41.25 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on January 9, 2024, subject to the satisfaction of customary conditions.

Kymera intends to use the net proceeds from the offering to continue to advance its pipeline of preclinical and clinical degrader programs that are designed to address large patient populations with significant need and clear commercial opportunity, and for working capital and other general corporate purposes. Kymera may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or technologies to continue to build its pipeline, research and development capabilities and its intellectual property position.

Morgan Stanley, J.P. Morgan and TD Cowen are acting as joint lead bookrunning managers for the offering. UBS Investment Bank is also acting as a bookrunning manager.

The securities described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 (No. 333-259955) that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 1, 2021. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement.

A final prospectus supplement related to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and an accompanying prospectus related to the offering may also be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by telephone at (833) 297-2926, or by email at Prospectus_ECM@cowen.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, and include, but are not limited to, statements regarding the expected gross proceeds from the offering, the anticipated use of proceeds from the offering and completion and timing of the public offering. Any forward-looking statements are based on Kymera’s current expectations, forecasts, and assumptions and are subject to a number of risks and uncertainties that could cause actual outcomes and results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Kymera’s Annual Report on Form 10-K for the year ended December 31, 2022 and its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, as well as in the prospectus supplement related to the public offering. Forward-looking statements contained in this announcement are based on information available to Kymera as of the date hereof and are made only as of the date of this release. Kymera undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Kymera’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Kymera.

Investor Contact: Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com 857-285-5300

Media Contact: Todd Cooper  Senior Vice President, Corporate Affairs  media@kymeratx.com  857-285-5300

FAQ

What did Kymera Therapeutics announce?

Kymera Therapeutics announced the pricing of its underwritten public offering of $275 million of shares of its common stock and pre-funded warrants to purchase shares of its common stock.

When is the offering expected to close?

The offering is expected to close on January 9, 2024.

What does Kymera Therapeutics intend to use the net proceeds for?

Kymera Therapeutics intends to use the net proceeds for advancing its pipeline of preclinical and clinical degrader programs, working capital, and other general corporate purposes.

Who are the lead bookrunning managers for the offering?

Morgan Stanley, J.P. Morgan, and TD Cowen are acting as joint lead bookrunning managers for the offering.

How can I obtain copies of the final prospectus supplement related to the offering?

Copies of the final prospectus supplement related to the offering may be obtained from Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, or Cowen and Company, LLC.